AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05605483 — intervention group
Intervention type: OTHER
Intervention: Waitlisted control
Description: Schools where the school district has not yet installed salad bars
Study NCT05605483 — intervention group
Intervention type: OTHER
Intervention: Salad bar post-COVID
Description: Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
Study NCT03212664 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: physical therapy exercises
Study NCT00805545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
Study NCT00805545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
Study NCT01628094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048
Study NCT01628094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591
Study NCT01091272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Planned single PO 120mg and 210mg doses of PF-04995274
Study NCT01091272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
Study NCT02274142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Encapsulated material
Description: restoration with encapsulated ionomer cement
Study NCT02274142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encapsulated glass ionomer cement (EQUIA - GC Corp).
Study NCT02274142 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: powder-liquid glass ionomer cement (Fuji IX - GC Corp)
Study NCT01628094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5466731
Study NCT01457612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strawberry
Description: 20g twice per day (BID) in beverage
Study NCT01457612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo1
Description: Placebo Beverage 1 without fiber
Study NCT01457612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo2
Description: Placebo Beverage 2 with Fiber
Study NCT00551577 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy (Carboplatin/Docetaxel)
Description: 3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
Study NCT01628094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Study NCT01628094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Study NCT05369026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single leg immobilization
Description: 2 weeks of single-leg immobilization
Study NCT05369026 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Single leg immobilization
Description: 2 weeks of single-leg immobilization
Study NCT01284270 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI
Study NCT04426370 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Physical examination and questionnaires
Study NCT04070170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy
Description: Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons
Study NCT04070170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic force
Description: Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
Study NCT04070170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic force
Description: Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
Study NCT04602676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rehydration calculator application with DEP algorithm
Description: 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.
Study NCT04602676 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rehydration calculator application
Description: 4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted low dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted high dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
Study NCT03814590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study NCT03814590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline solution)
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study NCT00961922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: 30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
Study NCT00961922 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo feedback
Description: Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
Study NCT02843581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system
Study NCT02843581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system
Study NCT02843581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Nutral killer cell immunotherapy for more than 6 times
Study NCT01288508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supra Fiber
Description: 2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
Study NCT01288508 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: 1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
Study NCT01669941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPTp-SP
Description: 3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
Study NCT01669941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPTp-DP
Description: At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
Study NCT01669941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISTp-DP
Description: At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
Study NCT01308723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441
Description: escalating doses iv
Study NCT01308723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441
Description: iv every 2 weeks
Study NCT01308723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg orally twice daily to once every other day
Study NCT01308723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: 400 mg orally twice daily to once every other day
Study NCT01254513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks + Prednisone
Description: * Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously
Study NCT01254513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel weekly+ Prednisone
Description: * Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously
Study NCT03230747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN M3 System
Description: SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
Study NCT00551577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy (Carboplatin/Docetaxel)
Description: 2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
Study NCT02147054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT02147054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
Study NCT02407834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S1
Description: Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
Study NCT02407834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S2
Description: Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
Study NCT02407834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S3
Description: Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
Study NCT02407834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: S4
Description: Immersion in Saline solution for 20 minutes, during 7 days.
Study NCT03680703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Behavioral Weight Loss
Description: Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
Study NCT04178031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD insertion
Description: Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman.
Study NCT01633294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin + gentamicin
Description: ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
Study NCT00433316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 1% ropivacaine
Study NCT00433316 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aeroneb Pro Nezulizer, Aerogen, Ireland
Description: Aeroneb Pro Nezulizer, Aerogen, Ireland
Study NCT00949455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study NCT00949455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT03356886 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulative Technique
Description: 1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
Study NCT03356886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Technique
Description: 1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
Study NCT02200601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seipher Wellness
Study NCT01580228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m\^2 on Day 1, 10 mg/m\^2 on Day 8, and 14 mg/m\^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
Study NCT01580228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
Study NCT01101529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant (Emend)
Description: Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
Study NCT01101529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered instead of Emend
Study NCT03377517 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiosurgical hypophysectomy
Description: Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
Study NCT02471144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental : Secukinumab low dose
Description: Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
Study NCT02471144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Secukinumab high dose
Description: Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
Study NCT02471144 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Secukinumab Placebo
Description: Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
Study NCT02471144 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Etanercept
Description: Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
Study NCT02428829 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Attempt walking from 4 hours post operatively, on the day of their surgery.
Description: Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
Study NCT02428829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - standard treatment
Description: standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03878524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO